Neoprobe's largest investor to drop proxy fight threat

Neoprobe has reached an agreement with Platinum Montaur Life Sciences regarding the nomination of directors. As a result of the agreement, Peter Drake and Jess Emery Jones will fill two current board vacancies with terms expiring at the 2012 annual meeting. Both also will be nominated for election as directors for terms expiring at the company's 2014 annual meeting. Platinum had been pushing for adding more biotech expertise to the board. Neoprobe release | Story